
Opinion|Videos|July 16, 2026
Historic Treatments and the Need for Menin Inhibitors
Menin inhibitors offer new hope in relapsed KMT2A/MP1 AML, controlling disease to reach remission and allogeneic stem cell transplant.
Episodes in this series

In this episode, Sanja Zepcan, PharmD, BCPS, BCOP, explores the limitations of salvage chemotherapy regimens in this patient population and introduces allogeneic stem cell transplant as the only curative option. She discusses why menin inhibitors represent a paradigm shift as a bridge to transplant and shares why pharmacists must understand transplant eligibility as a meaningful treatment end point, not a distant contingency.
Latest CME
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
3
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5






































































































